Vasculitis

Avacopan Superior to Standard Therapy in Renal Function in ANCA-Associated Vasculitis

Publish Date November 8, 2020

Study authors evaluated the effect of complement C5a receptor inhibitor avacopan on renal function in ANCA-associated vasculitis.

Hypothyroidism Associated With Different Forms of ANCA-Associated Vasculitis

Publish Date November 7, 2020

Researchers assessed thyroid disease risk between the different forms of ANCA-associated vasculitis (AAV), and compared the clinical features of AAV in patients with and without thyroid disease.

Evaluating Glucocorticoid-Related Damage in Elderly Patients With ANCA-Associated Vasculitis

Publish Date October 28, 2020

In a safety outcome analysis, researchers assessed treatment-related damage in patients with elderly-onset ANCA-associated vasculitis.

Myeloperoxidase ANCA-Associated Vasculitis May Occur After Infection and Regress After Its Resolution

Publish Date October 23, 2020

Researchers performed a systematic review to identify cases of infection-induced antimyeloperoxidase ANCA-associated vasculitis.

Case Study Reports First Known Case of Neutrophilic Arterial Vasculitis in COVID-19

Publish Date October 19, 2020

Authors of this case study reported the first case of neutrophilic arterial vasculitis in COVID-19.

FDA to Review Avacopan for ANCA-Associated Vasculitis

Publish Date September 23, 2020

Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.

Specimen Length, Number of Sections Linked to Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis

Publish Date August 25, 2020

Researchers investigated the association between specimen length and number of sections evaluated and the diagnostic yield of temporal artery biopsy for giant cell arteritis.

Iloprost May Be Useful in the Treatment of COVID-19 Vasculopathy

Publish Date July 27, 2020

Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.

Avacopan NDA Submitted for ANCA-Associated Vasculitis

Publish Date July 16, 2020

ChemoCentryx, Inc has submitted a NDA to the FDA for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Long-Term Rituximab Linked to Reduced Incidence of ANCA-Associated Vasculitis

Publish Date June 12, 2020

Extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis relapse in GPA or MPA.